Notice Number: NOT-AI-16-087
Key Dates
Release Date: October 5, 2016
Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
Purpose
On February 25, 2016, the NIAID issued Funding Opportunity Announcement (FOA) PAR-16-115 "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)." The purpose of this Notice is to alert the scientific community of a clarification in the purpose and research objectives and revision of research strategy instructions of this FOA.
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Purpose
Current Language:
The purpose of this Funding Opportunity Announcement (FOA) is to support the optimization of mAb or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir.
Revised Language:
The purpose of this Funding Opportunity Announcement (FOA) is to support the optimization of mAb or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir. For the purpose of this FOA, optimization refers to the molecular engineering of mAb and/or their modification during or after production such that they are no longer native.
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Specific Areas of Research Interest
Current Language:
This FOA will support applications that propose hypothesis-driven mechanistic studies aimed at the optimization of mAb or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir. Areas of interest include, but are not limited to:
For the purposes of this FOA, the following HIV-specific mAb or mAb derivatives are within scope:
Applications proposing any of the following research topics will NOT be supported under this FOA:
Revised Language:
This FOA will support applications that propose hypothesis-driven mechanistic studies aimed at the optimization of mAb or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir. Areas of interest include, but are not limited to:
For the purposes of this FOA, the following HIV-specific mAb or mAb derivatives are within scope:
Applications proposing any of the following research topics will NOT be supported under this FOA:
Part 2. Section IV. Application and Submission Information
Current Language:
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Revised Language:
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Research Strategy:
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
All other aspects of this FOA remain the same.
Inquiries
Please direct all inquiries to:
Stephen Smiley, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3071
Email: stephen.smiley@nih.gov
Jeymohan Joseph, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 240-627-3869
Email: jjeymoha@mail.nih.gov